Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals Inc (NQ: MDGL )

248.31 +5.82 (+2.40%)
Streaming Delayed Price Updated: 11:03 AM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Madrigal Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
The 3 Best Biotech Stocks to Buy Now: September 2023
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize. 
Via InvestorPlace
3 Biotech Stocks That Wall Street Analysts Can’t Get Enough Of
Worries about biotech stocks are way overdone, so the sector should make a big comeback in the coming months. 
Via InvestorPlace
The 3 Most Promising Pharma Stocks to Own Now
A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride. 
Via InvestorPlace
3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?
NASH treatments are projected to be one of the most sought-after indications in the coming years. 
Via The Motley Fool
Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It
NASH is a surprisingly common ailment, and the first treatments are on the way. 
Via The Motley Fool
Why Madrigal Pharmaceuticals Stock Is Marching Higher Today
Two key tailwinds appear to be lifting the stock today. 
Via The Motley Fool
Analyst Expectations for Madrigal Pharmaceuticals's Future
Via Benzinga
Why Madrigal Pharmaceuticals Stock Is Slumping Today
The biotech's shares briefly plunged following its 2023 Q1 earnings report. 
Via The Motley Fool
Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy?
Novo Nordisk received some good news in a recent physician survey. 
Via The Motley Fool
Madrigal Stock Pops As It Makes Inroads Into What Could Be A $160 Billion Market
Madrigal is working on gaining FDA approval for what could be the first NASH treatment. 
Via Investor's Business Daily
Terns Pharmaceuticals Is "Attractively Priced" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says
Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) shares lost more than 25% of their value due to investor pressure it faced after Eli Lilly And Co (NYSE: LLY) announced data from retatrutide that was... 
Via Benzinga
2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall Street
Recent moves to the upside could be the beginning of a much larger bull run. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health. 
Via Benzinga
Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug
The FDA's advisors voted resoundingly against accelerated approval for obeticholic acid. 
Via Investor's Business Daily
Why These 3 Nasdaq Stocks Buckled Today
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today. 
Via The Motley Fool
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in  
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotechs That Might Get Bought Out in 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
Why Madrigal Pharmaceuticals Stock Gained 20% This Week
Two key tailwinds fueled a surge in the biotech's share price this week. 
Via The Motley Fool
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is... 
Via Benzinga
Why Top 1% Biotech Madrigal Pharmaceuticals Just Surged Closer To A Breakout
Shares are closing in on a buy point after retaking their 50-day moving average. 
Via Investor's Business Daily
5 Best Stocks to Buy in April
These powerful trends should yield stellar returns for investors in April and beyond. 
Via The Motley Fool
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
Viking Therapeutics stock might in the midst of a historic run. 
Via The Motley Fool
Is Viking Therapeutics a Smart Buy on the Dip?
The stock recently fell around 25% for reasons that had nothing to do with its lead program. 
Via The Motley Fool
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle
Meanwhile, the company is facing a stout rival in the form of Madrigal Pharmaceuticals. 
Via Investor's Business Daily
1 Incredible Growth Stock That Could Turn $200,000 Into $1 Million by 2030
This clinical-stage biopharma stock could harbor one of the best-selling drugs of all time. 
Via The Motley Fool
3 Incredible Growth Stocks to Buy if the Market Dips
These top growth stocks sport premium valuations for a very good reason. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.